Skip to main content
. 2023 Mar 21;14(5):848–857. doi: 10.1039/d3md00040k
Antibodies
Specific single-chain antibody fragments Fibril surface 2nd nucleation ↓↓ 56
Aducanumab (murine) Fibril surface 2nd nucleation ↓↓ 15
Gantenerumab (murine) Fibril-ends Elongation ↓↓ 15
Bapineuzumab (murine) Fibril-ends Elongation ↓↓ 15
Solanezumab (murine) Monomers Primary nucleation ↓↓ 15
a

Only determined by fit analysis and not confirmed by seeding experiments.